Professor

EQS-News: DATAGROUP Gives Positive Outlook for Current Fiscal Year

Retrieved on: 
Wednesday, April 10, 2024
Cloud, Technische Hochschule Nürnberg, EUR, Annual, Speech, Climate change, Growth, HIRO, Environment, WKN, FY, CFO, Partnership, Intelligence, Black, Artificial intelligence, Policy, SAP, Acquisition, AI, Social responsibility, Professor, Organization, Annual general meeting, Investment, IP, SME, Sustainability, Tree, Human resources

At today's Annual General Meeting of DATAGROUP SE at the company's headquarters in Pliezhausen near Stuttgart, 73.1 % of the voting share capital was represented.

Key Points: 
  • At today's Annual General Meeting of DATAGROUP SE at the company's headquarters in Pliezhausen near Stuttgart, 73.1 % of the voting share capital was represented.
  • "The economic situation remains challenging, but DATAGROUP is excellently positioned and I am therefore optimistic about the future."
  • DATAGROUP intends to invest EUR 6m in these areas in the current fiscal year and thus lay the foundation for further success and future growth.
  • Inorganic growth through acquisitions will continue to be an important pillar of success in the current fiscal year.

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

Retrieved on: 
Wednesday, April 3, 2024
EGFR, Gene, Nested polymerase chain reaction, Professor, Cancer Institute, Circulating free DNA, Neoplasm, TCR, Research institute, QGEN, Research, PCR, Central business district, NGS, DNA, BRAF, Diagnosis, WIA, Cancer, Immune system, Liquid biopsy, UMI, Mutation, Genetics, Human genetics, Senior, AACR, Medical school, QIAGEN, Poster, Environment, IVD, Urine

Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.

Key Points: 
  • Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.
  • EGFR and BRAF are genes essential for normal cell growth and function, but mutations in these genes can result in cancer development.
  • To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors.
  • Learn more about QIAGEN’s offering at the AACR Annual Meeting 2024, (booth #922 in the San Diego Convention Center) and poster presentations highlighting new solutions in digital PCR, NGS and preanalytical workflows at https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-mee... .

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Retrieved on: 
Monday, April 1, 2024
FACC, Weill Cornell Medicine, Professor, Safety, NewYork-Presbyterian Hospital, Paroxysmal attack, Paroxysmal supraventricular tachycardia, Efficacy, RAPID, American College, Sinus rhythm, Hospital, Division, Signs and symptoms, Conversion, Pharmaceutical industry

MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month.

Key Points: 
  • MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month.
  • The company will deliver oral and poster presentations at the American College of Cardiology annual meeting (ACC24) , to be held April 6-8th in Atlanta, Georgia, and a poster presentation at the annual meeting of the European Heart Rhythm Association (EHRA) , to be held April 7-9th in Berlin, Germany.
  • The presentations will be available following the embargo at https://MilestonePharma.com .
  • Multi-Center, Open-Label Study of the Efficacy and Safety of Etripamil Nasal Spray Self-Administered For Multiple Episodes of Symptomatic Supraventricular Tachycardia Without Supervision (Phase 3, NODE-303)
    James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
    Symptom-prompted, Self-administered Intranasal Etripamil for Termination of Paroxysmal Supraventricular Tachycardia in the RAPID Study: Relationship Among Etripamil-Induced Reduction in Tachycardia Rates, Conversion to Sinus Rhythm, and Improvement in Patient Symptoms
    James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
    Characterising paroxysmal supraventricular tachycardia episodes by patient-perceived episode duration, symptoms, and severity: longitudinal patient-reported outcomes
    David Bharucha, M.D., Ph.D., FACC, Chief Medical Officer of Milestone Pharmaceuticals, Inc.

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

Retrieved on: 
Wednesday, March 27, 2024
WEE1, Netherlands Cancer Institute, Bernards, Cell, Professor, Malignancy, Neoplasm, Cancer, Death, Cancer Discovery (journal), Vaccine

PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” The finding opens a potentially new treatment strategy in addition to LIXTE’s current three clinical trials.

Key Points: 
  • The deliberate hyper-activation of cancer signals becomes lethal when combined with an inhibitor of the WEE1 kinase.
  • This well-tolerated combination proved to be highly effective in killing colon cancer cells in animal models of cancer and in cell culture.
  • Resistance to LB-100 therapy, however, has been shown to be associated with cancer cells becoming less malignant.
  • Although cancer-causing signals force cancer cells to become more cancerous, the hyper-activation of these signals by LB-100 forces cancer cells to suppress these signals and thus become less cancerous.

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Retrieved on: 
Wednesday, March 27, 2024
Multiple, Professor, ETV, SAN, Patient, Hepatology, Southern Medical University, SHBG, Doctor of Science, University, Doctor of Philosophy, MBBS, MASH, MBA, Science, Therapy, Hepatitis, Part, Division, University of Hong Kong, Infection, CHB, Pharmaceutical industry

The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.

Key Points: 
  • The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.
  • “We are pleased to present these additional Phase 1 data for ALG-055009 and ALG-000184 at APASL 2024.
  • We continue to believe our molecule has the potential to be best-in-class,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “In addition, the three ALG-000184 oral presentations demonstrate a consistent effect in the reduction of key viral markers.

GTG Global Collaborations and Innovation Update

Retrieved on: 
Tuesday, March 26, 2024
Breast cancer, Health, General practice, Professor, BRCA, Public, Public health, Disease, GTG, Risk, Patient, PRS, Research, ASX, Breast, Mammography, University, Royal Melbourne Hospital, Trial of the century, WHI, Risk assessment, Sonneborn–Berger score, Council, Biobank, Publication, Clinical trial, Cancer, CLIA, Medical research, Colorectal cancer, University of Melbourne, Government, UK Biobank, Pharmaceutical industry

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

Key Points: 
  • MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.
  • GTG is one of the co-co-principal investigators of this trial led by Professor Jon Emery.
  • GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care.
  • Leveraging this approach GTG is expanding the portfolio with the following new tests:
    Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS.

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Retrieved on: 
Tuesday, March 26, 2024
Tao, Internal medicine, Professor, Patient, Pulmonology, Executive Committee, Drug, Therapy, Chairperson, Sensation, Genentech, NSW, St George's Hospital, Harvard University, MTR, Pediatrics, Stanford University, Teaching hospital, Critical care, Outline of health sciences, KCP, Neuroinflammation, UCSF, Research, Acquisition, University, Management, MPH, Drug development, Atopic dermatitis, Entrepreneurship, Critical Care Medicine (journal), Adolescence, Contact dermatitis, Science, Division, KRYS, Pharmaceutical industry

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.

Key Points: 
  • Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
  • At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
  • Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
  • To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.

Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Abstract Big Data Bayesian Truths to Be Covered in Oral Presentation at the 24th ECCMID Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Infectious Diseases, Hospitals, Health Technology, Genetics, Clinical Trials, Congress, Midwestern University, BCPS, Doctor of Pharmacy, Professor, AUC, Patient, Big data, Vancomycin, Safety, ESCMID, ECCMID, European, Infection, Pharmaceutical industry

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.

Key Points: 
  • ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.
  • Abstract co-authored Dr. Sharmeen Roy, PharmD, BCPS , Chief Strategy and Science Officer and Paul Sabourenkov , Lead Bioinformatician at DoseMe.
  • What: Abstract 05305, Big Data Bayesian Truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.
  • Details: Title: Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.

Clinical Data Supports Novel Continuous Calprotectin Monitoring Wearable for IBD Management by EnLiSense

Retrieved on: 
Monday, April 8, 2024
Technology, Medical Devices, Health Technology, Nanotechnology, Other Health, Biotechnology, Hardware, Managed Care, Health, Data Management, Moses Austin, Conditional sentence, University, Professor, IL-6, Perspiration, Patient, Inflammation, Biomarker, Research, AI, Doctor of Philosophy, Senior, IBD, Translation, Management, C-reactive protein, Inflammatory bowel disease, Inflammatory Bowel Diseases, Trial of the century, CRP, Pharmaceutical industry

The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.

Key Points: 
  • The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.
  • These results not only affirm the accuracy of the IBD Aware device, but demonstrate its utility in the shifting paradigm of proactive IBD management that emphasizes continuous, data-driven decision-making.
  • “The IBD Aware device exemplifies our dedication to empowering healthcare professionals and enhancing patient outcomes through remote and continuous monitoring."
  • EnLiSense is pioneering work to build a future where proactive, personalized, and precision remote patient monitoring becomes the standard in chronic disease management.

Hackensack Meridian Hackensack University Medical Center Among First Hospitals in the World To Acquire and Use the Da Vinci 5 Multiport Robotic Surgical System

Retrieved on: 
Tuesday, April 9, 2024
Hackensack University Medical Center, Vibration, Hysterectomy, Health, Surgeon, Hackensack Meridian Health, Professor, Education, Patient, Hospital, Trauma, Research, Artificial intelligence, Force, Insufflation, Workflow, Patient safety, Fatigue, Intuitive Surgical, Intuition, Engineering, Dentistry

HACKENSACK, N.J., April 9, 2024 /PRNewswire/ -- Hackensack Meridian Hackensack University Medical Center, a center of excellence and an international leader in robotic-assisted surgery, was selected to be one of only 14 centers in the world, and the only in New Jersey, New York and Connecticut, to acquire the Intuitive Surgical da Vinci 5 multiport surgical system. With more than 10,000 times the computing power and the first-of-its-kind force-sensing technology, the da Vinci 5 is the most advanced surgical technology available.

Key Points: 
  • The Hackensack University Medical Center team performed the first procedures ever using the new system to treat the four patients on Monday, April 1, 2024.
  • Da Vinci 5 builds on Intuitive's da Vinci Xi's highly functional design, which surgeons and care teams around the world have used in more than 7 million procedures to date.
  • Expanded computing power and advanced data capabilities: Da Vinci 5 has more than 10,000 times the computing power of da Vinci Xi.
  • Robotic surgery innovations and "firsts" include:
    Robotic surgery began at Hackensack University Medical Center in 2000 with two da Vinci™ robots.